AstraZeneca Pharma India Ltd., a leading science-led biopharmaceutical company, reported robust financial results for the fiscal year ended March 31, 2024 (FY24).
Key Financial Highlights:
Total Revenue: ₹1,330 crore, a 29% increase compared to the previous fiscal year.
Revenue from Operations: ₹1,296 crore, also a 29% increase.
Profit Before Tax (PBT): ₹220 crore, demonstrating a 64% growth.
PBT before exceptional items was ₹201 crore, up 17% YoY.
Earnings Per Share (EPS): ₹64.6, a significant 63% growth.
Dividend: The Board of Directors recommended a final dividend of ₹24 per equity share for FY24.
Additional Key Points:
Strong Product Sales Growth: AstraZeneca India's product sales crossed the ₹1,000 crore mark for the first time.
Growth Strategy: The company attributed its strong performance to the successful execution of its "growth through innovation" strategy.
Focus Areas: AstraZeneca India continues to focus on pioneering science and leading in specialist disease areas in the country.
Management Commentary:
Sanjeev Panchal, Country President and Managing Director of AstraZeneca India, expressed pride in the company's consistent performance and highlighted FY24 as one of the strongest years for them in the country. He emphasized the company's commitment to innovation and leadership in specialist disease areas.
For Further Information:
AstraZeneca Pharma India Press Release: https://www.astrazeneca.in/media/press-releases/2024/AstraZeneca-Pharma-India-Limited-achieves-growth-of-29-percentage-for-financial-year-ended-March-31-2024.html
ICICI Direct Analysis: https://www.icicidirect.com/research/equity/rapid-results/astrazeneca-pharma-india-ltd
Comments